Immix Biopharma
potential to disrupt the oncology and immunology categories | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
32 of 64
Similar slides by Immix Biopharma
See diffirences between slides (animation)
Investor Presentation
December 2023
potential to disrupt the oncology and immunology categories | Immix Biopharma
Investor Presentation
November 2023
potential to disrupt the oncology and immunology categories | Immix Biopharma
Investor Presentation
November 2023
potential to disrupt the oncology and immunology categories | Immix Biopharma
Investor Presentation
November 2023
potential to disrupt the oncology and immunology categories | Immix Biopharma
Related slides by other companies
Erasca
Investor Presentation
January 2024
potential for rapid market entry and multiple ways to benefit patients with ras driven tumors | Erasca
Legend Biotech
IPO
May 2020
has the potential to eliminate car tumor cells i | Legend Biotech
SentiBio
SPAC
October 2021
armed car cells exhibit significantly improved killing of cancer cells a in tumor cell day post culture ratio i | SentiBio
Alkermes
Results
June 2021
artistry phase efficacy expansion initiated following determination of subcutaneous | Alkermes
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
March 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights